VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Lymphoma DNA vaccine VαVβVβ-FrC
Vaccine Information
  • Vaccine Name: Lymphoma DNA vaccine VαVβVβ-FrC
  • Target Pathogen: Cancer
  • Target Disease: Cancer
  • Vaccine Ontology ID: VO_0004398
  • Type: DNA vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse
  • Fragment C from tetanus toxin gene engineering:
    • Type: DNA vaccine construction
    • Description: This vaccine encoded T-cell antigen receptor Valpha, Vbeta, and Fragment C (Thirdborough et al., 2002).
    • Detailed Gene Information: Click Here.
  • DNA vaccine plasmid:
    • DNA vaccine plasmid name:
    • DNA vaccine plasmid VO ID: VO_0000132
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Mouse Response

  • Vaccine Immune Response Type: VO_0000286
  • Efficacy: Vaccination with the DNA construct VαVβCβ-FrC induced strong protection against challenge with C6VL, compared with nonvaccinated control mice and mice vaccinated with FrC alone (P < 0.001). Vaccinations with VαVβ-FrC, VβCβ-FrC, or VαVβCβ alone were also completely ineffective. The protective response generated was specific for C6VL, with no protection induced against TCL-1, an unrelated T-cell tumor. The pattern of protection has been confirmed in two subsequent experiments, with survival rates of mice vaccinated with VαVβCβ-FrC ranging from 50 to 80%, whereas the other constructs were ineffective at prolonging survival (Thirdborough et al., 2002).
References
Thirdborough et al., 2002: Thirdborough SM, Radcliffe JN, Friedmann PS, Stevenson FK. Vaccination with DNA encoding a single-chain TCR fusion protein induces anticlonotypic immunity and protects against T-cell lymphoma. Cancer research. 2002; 62(6); 1757-1760. [PubMed: 11912151].